This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Khan, O. A Articles by Lisak, R. P Search for Related Content PubMed PubMed Citation Articles by Khan, O. A Articles by Lisak, R. P Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYCLOPHOSPHAMIDE Medline Plus Health Information Multiple Sclerosis Social Bookmarking                         What's this?

Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, USA

Marina Zvartau-Hind

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, USA

Christina Caon

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, USA

Moeen U Din

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, USA

Mickey Cochran

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, USA

Deena Lisak

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, USA

Alexandros C Tselis

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, USA

John A Kamholz

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, USA

James Y Garbern

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, USA

Robert P Lisak

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, USA

Fourteen consecutive clinically definite relapsing-remitting multiple sclerosis (MS) patients were treated with monthly intravenous cyclophosphamide (CTX) for 6 months. All had experienced severe clinical deterioration during the 12 months prior to treatment with CTX despite treatment with conventional immunomodulating agents and intravenous methylprednisolone. Treatment with CTX led to improvement and neurologic stability within 6 months which was sustained for at least 18 months after the onset of treatment with CTX. Therapy with CTX was well tolerated. CTX may be of benefit in MS patients who experience rapid clinical worsening and are resistant to conventional therapy.

Key Words: immunosuppressive therapy • progressive multiple sclerosis • cyclophosphamide • corticosteroids • immunomodulating therapy

Multiple Sclerosis, Vol. 7, No. 3, 185-188 (2001)
DOI: 10.1177/135245850100700309


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Awad and O. Stuve Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms Therapeutic Advances in Neurological Disorders, November 1, 2009; 2(6): 357 - 368. [Abstract] [PDF]

				P. Rieckmann, A. Traboulsee, V. Devonshire, and J. Oger Review: Escalating immunotherapy of multiple sclerosis Therapeutic Advances in Neurological Disorders, November 1, 2008; 1(3): 181 - 192. [Abstract] [PDF]

				D R Smith, B Weinstock-Guttman, J A Cohen, X Wei, C Gutmann, R Bakshi, M Olek, L Stone, S Greenberg, D Stuart, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta Multiple Sclerosis, October 1, 2005; 11(5): 573 - 582. [Abstract] [PDF]

				H L Weiner and J A Cohen Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects Multiple Sclerosis, April 1, 2002; 8(2): 142 - 154. [Abstract] [PDF]